HLB

$2,000.00

Verified Ownership Structure
Detailed mapping of subsidiaries, affiliates, and equity-method entities, with full accounting treatment (full consolidation vs equity-method) and operational relevance to pipeline or financial outcomes.
Updated Financial Snapshot with USD Conversion
Q1 2025 financials converted to USD for global visibility. Includes cash runway estimation, asset/liability trend, and capital erosion analysis.
Clinical Pipeline Validation (Cross-Checked)
Full audit of active trials with ClinicalTrials.gov verification. Identifies false or misleading sponsor claims, misattributed assets (e.g., rivoceranib), and terminated trials still cited as successes.
Red Flag Matrix for Investors
Analyst-grade Risk Matrix highlighting operational drain points, cash burn, unreliable affiliates, and governance ambiguity.
Regulatory & Ethical Concerns Highlighted
Observations on lack of transparency in clinical disclosure, risk of misleading public information, and structural opacity that may impact valuation or strategic partnerships.

Target Audience:
Venture Capital, Private Equity, Institutional Investors, Corporate Strategy Units, Due Diligence Teams

Utility:
Ideal for pre-investment screening, technical audit, risk modeling, and benchmarking against oncology portfolio assets.

Access Password

This document is password-protected.
To open it, use the company’s stock exchange ID number as the password.

🔐 Example: 6 digit

Verified Ownership Structure
Detailed mapping of subsidiaries, affiliates, and equity-method entities, with full accounting treatment (full consolidation vs equity-method) and operational relevance to pipeline or financial outcomes.
Updated Financial Snapshot with USD Conversion
Q1 2025 financials converted to USD for global visibility. Includes cash runway estimation, asset/liability trend, and capital erosion analysis.
Clinical Pipeline Validation (Cross-Checked)
Full audit of active trials with ClinicalTrials.gov verification. Identifies false or misleading sponsor claims, misattributed assets (e.g., rivoceranib), and terminated trials still cited as successes.
Red Flag Matrix for Investors
Analyst-grade Risk Matrix highlighting operational drain points, cash burn, unreliable affiliates, and governance ambiguity.
Regulatory & Ethical Concerns Highlighted
Observations on lack of transparency in clinical disclosure, risk of misleading public information, and structural opacity that may impact valuation or strategic partnerships.

Target Audience:
Venture Capital, Private Equity, Institutional Investors, Corporate Strategy Units, Due Diligence Teams

Utility:
Ideal for pre-investment screening, technical audit, risk modeling, and benchmarking against oncology portfolio assets.

Access Password

This document is password-protected.
To open it, use the company’s stock exchange ID number as the password.

🔐 Example: 6 digit